ABT - Abbott Laboratories Stock Price, Fair Value and News

107.28USD0.00 (0.00%)Delayed as of 22 Apr 2024, 10:44 am ET

Market Summary

USD107.280.00

Delayedas of 22 Apr 2024, 10:44 am

0.00%

ABT Stock Price

View Fullscreen

ABT RSI Chart

ABT Valuation

Market Cap

186.2B

Price/Earnings (Trailing)

32.53

Price/Sales (Trailing)

4.64

EV/EBITDA

22.49

Price/Free Cashflow

36.8

ABT Price/Sales (Trailing)

ABT Profitability

EBT Margin

16.61%

Return on Equity

14.83%

Return on Assets

7.82%

Free Cashflow Yield

2.72%

ABT Fundamentals

ABT Revenue

Revenue (TTM)

40.1B

Rev. Growth (Yr)

1.49%

Rev. Growth (Qtr)

0.97%

ABT Earnings

Earnings (TTM)

5.7B

Earnings Growth (Yr)

54.31%

Earnings Growth (Qtr)

11%

Breaking Down ABT Revenue

52 Week Range

94.53115.83

(Low)(High)

Last 7 days

-1.7%

Last 30 days

-3.8%

Last 90 days

-6.4%

Trailing 12 Months

-2.8%

How does ABT drawdown profile look like?

ABT Financial Health

Current Ratio

1.64

Debt/Equity

0.35

Debt/Cashflow

0.53

ABT Investor Care

Dividend Yield

1.94%

Dividend/Share (TTM)

2.08

Buy Backs (1Y)

0.16%

Diluted EPS (TTM)

3.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	41.5B	40.2B	40.0B	40.1B
2022	44.5B	45.5B	45.0B	43.7B
2021	37.3B	40.2B	42.3B	43.1B
2020	32.1B	31.4B	32.2B	34.6B
2019	30.7B	30.9B	31.4B	31.9B
2018	28.4B	29.6B	30.4B	30.6B
2017	22.3B	23.6B	25.1B	27.4B
2016	20.4B	20.6B	20.7B	20.9B
2015	20.4B	20.5B	20.6B	20.4B
2014	19.6B	19.7B	20.0B	20.2B
2013	21.1B	20.7B	20.2B	19.7B
2012	35.1B	30.8B	26.2B	21.5B
2011	36.5B	37.3B	38.4B	38.9B
2010	31.7B	33.1B	34.0B	35.2B
2009	29.5B	29.7B	29.9B	30.8B
2008	26.8B	27.7B	28.6B	29.5B
2007	0	0	0	25.9B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Abbott Laboratories

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	moreland mary k	sold	-80,106	118	-676	executive vice president
Mar 01, 2024	earnhardt lisa d	sold	-82,239	118	-694	executive vice president
Mar 01, 2024	mccoy john a. jr.	sold	-55,932	118	-472	vice president
Mar 01, 2024	salvadori daniel gesua sive	sold	-114,116	118	-963	executive vice president
Mar 01, 2024	allen hubert l	sold	-101,080	118	-853	executive vice president
Mar 01, 2024	morrone louis h.	sold	-94,918	118	-801	executive vice president
Feb 29, 2024	wainer andrea f	sold (taxes)	-1,001,100	120	-8,339	executive vice president
Feb 29, 2024	boudreau philip p	sold (taxes)	-208,647	120	-1,738	senior vice president
Feb 29, 2024	earnhardt lisa d	sold (taxes)	-920,663	120	-7,669	executive vice president
Feb 29, 2024	salvadori daniel gesua sive	sold (taxes)	-1,065,320	120	-8,874	executive vice president

Which funds bought or sold ABT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	CHATHAM CAPITAL GROUP, INC.	added	0.44	36,864	1,027,710	0.19%
Apr 18, 2024	West Oak Capital, LLC	reduced	-0.37	-15,000	2,578,000	1.10%
Apr 18, 2024	Mirador Capital Partners LP	added	0.03	10,933	343,928	0.07%
Apr 18, 2024	Tributary Capital Management, LLC	reduced	-2.64	4,513	839,834	0.07%
Apr 18, 2024	Westhampton Capital, LLC	reduced	-11.48	-57,663	613,764	0.34%
Apr 18, 2024	WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST	unchanged	-	11,218,800	355,187,000	4.27%
Apr 18, 2024	WOODMONT INVESTMENT COUNSEL LLC	added	0.23	67,677	2,003,260	0.17%
Apr 18, 2024	PLIMOTH TRUST CO LLC	reduced	-0.85	79,361	3,404,680	0.91%
Apr 18, 2024	MV CAPITAL MANAGEMENT, INC.	reduced	-0.5	857,399	32,055,500	3.67%
Apr 18, 2024	Ironwood Financial, llc	unchanged	-	10,303	326,204	0.07%

Are Funds Buying or Selling ABT?

Are funds buying ABT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABT

No. of Funds

Unveiling Abbott Laboratories's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.01%	156,444,700	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	134,061,311	SC 13G/A
Feb 09, 2023	vanguard group inc	8.92%	155,480,794	SC 13G/A
Feb 06, 2023	blackrock inc.	8.0%	139,526,216	SC 13G/A
Feb 09, 2022	vanguard group inc	8.43%	149,152,264	SC 13G/A
Feb 01, 2022	blackrock inc.	7.8%	137,155,602	SC 13G/A
Feb 16, 2021	capital research global investors	4.9%	86,394,199	SC 13G/A
Feb 10, 2021	vanguard group inc	8.31%	147,272,920	SC 13G/A
Jan 29, 2021	blackrock inc.	7.5%	133,426,810	SC 13G/A
Feb 14, 2020	capital research global investors	6.4%	113,689,293	SC 13G/A

Recent SEC filings of Abbott Laboratories

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 15, 2024	ARS	ARS
Mar 15, 2024	DEF 14A	DEF 14A
Mar 15, 2024	DEFA14A	DEFA14A
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Abbott Laboratories)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Abbott Laboratories News

Latest updates

Abbott Laboratories Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1.0%	10,241	10,143	9,978	9,747	10,091	10,410	11,257	11,895	11,468	10,928	10,223	10,456	10,701	8,853	7,328	7,726	8,314	8,076	7,979	7,535	7,765
Costs and Expenses	-0.4%	8,461	8,496	8,436	8,238	8,787	8,640	8,881	8,983	9,090	8,382	8,831	8,347	8,269	7,358	6,656	6,968	6,925	6,878	6,773	6,796	6,600
S&GA Expenses	0.0%	2,724	2,723	2,740	2,762	2,973	2,731	2,757	2,787	3,048	2,767	2,726	2,783	2,570	2,302	2,276	2,548	2,413	2,440	2,434	2,478	2,359
R&D Expenses	4.2%	700	672	715	654	725	782	684	697	762	672	654	654	698	580	564	578	595	596	577	672	562
EBITDA Margin	5.8%	0.21*	0.20*	0.20*	0.21*	0.23*	0.25*	0.26*	0.25*	0.24*	0.24*	0.23*	0.22*	0.19*	0.17*	0.16*	0.18*	0.18*	0.18*	0.17*	-	-
Interest Expenses	-4.2%	159	166	159	153	154	141	132	131	131	133	134	135	136	137	134	139	164	167	168	171	186
Income Taxes	-14.5%	201	235	261	244	287	323	334	429	338	393	159	250	230	189	-11.00	89.00	191	143	96.00	-40.00	292
Earnings Before Taxes	7.4%	1,795	1,671	1,636	1,562	1,320	1,758	2,352	2,876	2,327	2,493	1,348	2,043	2,388	1,421	526	633	1,240	1,103	1,102	632	947
EBT Margin	7.3%	0.17*	0.15*	0.16*	0.17*	0.19*	0.21*	0.22*	0.20*	0.19*	0.20*	0.18*	0.17*	0.14*	0.12*	0.11*	0.13*	0.13*	0.12*	0.11*	-	-
Net Income	11.0%	1,594	1,436	1,375	1,318	1,033	1,435	2,018	2,447	1,989	2,100	1,189	1,793	2,162	1,232	537	564	1,049	960	1,006	672	654
Net Income Margin	10.5%	0.14*	0.13*	0.13*	0.14*	0.16*	0.18*	0.19*	0.17*	0.16*	0.17*	0.16*	0.15*	0.13*	0.10*	0.10*	0.11*	0.12*	0.10*	0.09*	-	-
Free Cashflow	73.3%	2,283	1,317	696	763	1,716	2,313	2,031	1,744	2,453	2,240	1,715	2,240	3,119	1,570	680	355	1,982	1,547	592	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.6%	73,214	72,090	73,354	73,794	74,438	72,801	74,202	74,007	21,174	73,795	73,269	72,785	20,955	69,043	68,776	66,777	18,007	68,539	68,427	67,610	67,173
Current Assets	0.0%	22,670	22,664	23,505	24,377	25,224	24,845	24,956	23,429	24,239	23,492	22,627	21,817	20,441	17,390	17,221	15,498	15,667	16,119	15,195	14,409	14,632
Cash Equivalents	2.8%	6,896	6,709	7,835	9,161	9,882	9,594	8,937	7,675	9,799	9,302	8,658	8,054	6,838	4,480	4,763	3,377	3,860	4,091	3,137	3,022	3,844
Inventory	-1.2%	6,570	6,650	6,871	6,673	6,173	5,734	5,899	5,691	5,157	5,261	5,439	5,387	5,012	5,152	5,202	4,568	4,316	4,392	4,352	4,085	3,796
Net PPE	6.3%	10,154	9,552	9,449	9,282	9,162	8,689	8,818	8,908	8,959	8,831	8,816	8,832	9,029	8,620	8,343	7,907	8,038	7,825	7,825	7,626	7,563
Goodwill	1.6%	23,679	23,300	23,300	22,927	22,799	22,284	22,744	23,179	23,200	23,300	23,500	23,384	23,700	23,300	23,100	22,927	23,200	23,046	23,329	23,209	23,300
Current Liabilities	6.1%	13,841	13,042	14,350	14,530	15,489	13,365	12,392	12,647	13,105	12,867	12,614	12,462	11,907	10,257	10,959	10,808	10,863	10,491	9,062	9,113	9,012
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	197	199	199	213	208	205	204	201	204	204	201	200
Long Term Debt	-6.1%	13,599	14,477	14,562	14,615	14,522	15,297	16,755	17,086	17,296	17,446	17,547	17,489	18,527	18,349	18,184	16,804	16,661	17,639	18,982	18,845	19,359
LT Debt, Current	2.8%	1,080	1,051	2,284	2,285	2,251	1,117	5.00	4.00	754	754	755	756	7.00	6.00	1,290	1,264	1,277	1,254	8.00	8.00	7.00
LT Debt, Non Current	-6.1%	13,599	14,477	14,562	14,615	14,522	15,297	16,755	17,086	17,296	17,446	17,547	17,489	18,527	18,349	18,184	16,804	16,661	17,639	18,982	18,845	19,359
Shareholder's Equity	3.0%	38,603	37,481	72.00	37,010	36,686	35,675	108	79.00	135	41.00	33,800	33,562	24,145	31,386	79.00	165	31,088	60.00	31,686	23.00	198
Retained Earnings	1.7%	37,554	36,920	36,355	35,868	35,257	35,115	34,487	33,295	31,528	30,376	29,053	28,669	27,627	26,266	25,669	25,786	25,847	25,440	25,045	24,613	24,560
Accumulated Depreciation	1.9%	11,779	11,559	11,477	11,323	11,050	10,617	10,640	10,613	10,405	10,351	10,258	9,865	9,764	9,352	9,031	8,800	8,761	8,518	8,506	8,279	8,143
Shares Outstanding	0.0%	1,740	1,740	1,740	1,742	1,753	1,756	1,758	1,762	1,775	1,775	1,779	1,777	1,773	1,774	1,771	1,769	1,768	1,768	1,769	-	-
Minority Interest	5.2%	224	213	230	222	219	209	226	230	222	216	229	226	219	209	220	209	213	202	208	204	198
Float	-	-	-	185,171	-	-	-	186,105	-	-	-	200,631	-	-	-	157,957	-	-	-	144,957	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	61.9%	3,038	1,877	1,203	1,143	2,326	2,780	2,410	2,065	3,067	2,701	2,128	2,637	3,798	2,066	1,322	715	2,416	1,948	1,060	712	1,765
Share Based Compensation	-2.6%	114	117	132	281	115	123	142	305	106	114	132	288	98.00	100	115	233	85.00	94.00	114	226	81.00
Cashflow From Investing	-30.0%	-824	-634	-1,213	-462	-632	-484	-264	-360	-671	-651	-264	-422	-731	-472	-619	-393	-489	-432	-498	-396	-496
Cashflow From Financing	12.3%	-2,052	-2,340	-1,289	-1,410	-1,457	-1,543	-813	-3,823	-1,886	-1,377	-1,264	-967	-787	-1,915	658	-735	-2,185	-513	-449	-1,142	-4,776
Dividend Payments	0%	888	888	890	890	823	826	828	832	798	801	803	800	641	639	642	638	568	569	568	565	495
Buy Backs	12850.0%	259	2.00	426	540	685	798	5.00	2,307	974	579	471	275	161	2.00	4.00	236	496	1.00	4.00	217	104

ABT Income Statement

2023-12-31

Consolidated Statement of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Sales	$ 40,109	$ 43,653	$ 43,075
Cost of products sold, excluding amortization of intangible assets	17,975	19,142	18,537
Amortization of intangible assets	1,966	2,013	2,047
Research and development	2,741	2,888	2,742
Selling, general and administrative	10,949	11,248	11,324
Total Operating Cost and Expenses	33,631	35,291	34,650
Operating Earnings	6,478	8,362	8,425
Interest expense	637	558	533
Interest income	(385)	(183)	(43)
Net foreign exchange (gain) loss	41	2	1
Other (income) expense, net	(479)	(321)	(277)
Earnings before Taxes	6,664	8,306	8,211
Taxes on Earnings	941	1,373	1,140
Net Earnings	$ 5,723	$ 6,933	$ 7,071
Basic earnings per common share (in dollars per share)	$ 3.28	$ 3.94	$ 3.97
Diluted earnings per common share (in dollars per share)	$ 3.26	$ 3.91	$ 3.94
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,740	1,753	1,775
Dilutive Common Stock Options (in shares)	9	11	14
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,749	1,764	1,789
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	5	3	0

ABT Balance Sheet

2023-12-31

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,896	$ 9,882
Investments, primarily bank time deposits and U.S. treasury bills	383	288
Trade receivables, less allowances of — 2023: $444; 2022: $500	6,565	6,218
Inventories:
Finished products	3,946	3,805
Work in process	807	680
Materials	1,817	1,688
Total inventories	6,570	6,173
Other prepaid expenses and receivables	2,256	2,663
Total current assets	22,670	25,224
Investments	799	766
Property and equipment, at cost:
Land	529	511
Buildings	4,161	4,053
Equipment	15,179	14,164
Construction in progress	2,064	1,484
Property and equipment, at cost	21,933	20,212
Less: accumulated depreciation and amortization	11,779	11,050
Net property and equipment	10,154	9,162
Intangible assets, net of amortization	8,815	10,454
Goodwill	23,679	22,799
Deferred income taxes and other assets	7,097	6,033
Total Assets	73,214	74,438
Current liabilities:
Trade accounts payable	4,295	4,607
Salaries, wages and commissions	1,597	1,556
Other accrued liabilities	5,422	5,845
Dividends payable	955	887
Income taxes payable	492	343
Current portion of long-term debt	1,080	2,251
Total current liabilities	13,841	15,489
Long-term debt	13,599	14,522
Post-employment obligations and other long-term liabilities	6,947	7,522
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	0	0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,883,852; 2022: 1,986,519,278	24,869	24,709
Common shares held in treasury, at cost — Shares: 2023: 253,807,494; 2022: 248,724,257	(15,981)	(15,229)
Earnings employed in the business	37,554	35,257
Accumulated other comprehensive income (loss)	(7,839)	(8,051)
Total Abbott Shareholders’ Investment	38,603	36,686
Noncontrolling interests in subsidiaries	224	219
Total Shareholders’ Investment	38,827	36,905
Total Liabilities and Shareholders' Investment	$ 73,214	$ 74,438

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, MÃƒÂ©niÃƒÂ¨re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

CEO	Mr. Robert B. Ford
WEBSITE	abbott.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	65535

Abbott Laboratories Frequently Asked Questions

What is the ticker symbol for Abbott Laboratories? What does ABT stand for in stocks?

ABT is the stock ticker symbol of Abbott Laboratories. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abbott Laboratories (ABT)?

As of Fri Apr 19 2024, market cap of Abbott Laboratories is 186.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers. The fair value of Abbott Laboratories is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abbott Laboratories is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abbott Laboratories a good stock to buy?

The fair value guage provides a quick view whether ABT is over valued or under valued. Whether Abbott Laboratories is cheap or expensive depends on the assumptions which impact Abbott Laboratories's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABT.

What is Abbott Laboratories's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ABT's PE ratio (Price to Earnings) is 32.53 and Price to Sales (PS) ratio is 4.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abbott Laboratories's stock?

In the past 10 years, Abbott Laboratories has provided 0.126 (multiply by 100 for percentage) rate of return.